Centessa Pharmaceuticals plc (CNTA)

The total asset value of Centessa Pharmaceuticals plc (CNTA) stood at $ 434 Mln as on 31-Mar-23

The share price of Centessa Pharmaceuticals plc (CNTA) is $5.620000 (NASDAQ) as of 02-Oct-2023 16:00 EDT. Centessa Pharmaceuticals plc (CNTA) has given a return of 39.8% in the last 1 years.

Centessa Pharmaceuticals plc (CNTA) has a market capitalisation of $ 430 Mln as on 02-Jun-2023. As per Value Research classification, it is a company.

The P/B ratio of Centessa Pharmaceuticals plc (CNTA) is 0.98 times as on 02-Jun-2023, a -0.61% premium to its peers’ median range of 2.54 times.

Since, TTM earnings of Centessa Pharmaceuticals plc (CNTA) is negative, P/E ratio is not available.

Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Centessa Pharmaceuticals plc (CNTA) and enter the required number of quantities and click on buy to purchase the shares of Centessa Pharmaceuticals plc (CNTA).

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders. The company also develops LB101, a PD-L1xCD47 LockBody, which is designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874 in alpha-1 antitrypsin deficiency, a dual-STAT3/5 degrader program in acute myeloid leukemia (AML); MGX292, a protein-engineered variant of human bone morphogenetic protein 9 (BMP9) for the treatment of pulmonary arterial hypertension (PAH); and OX2R Agonists compounds are currently in development for the treatment of narcolepsy, including TAK-861. In addition, its products pipeline comprises CBS001, a neutralizing therapeutic mAb to the inflammatory membrane form of LIGHT for inflammatory / fibrotic diseases; and CBS004, a therapeutic mAb targeting BDCA-2 for the potential treatment of autoimmune diseases, as well as earlier-stage preclinical assets, including ORX750, an orally administered, selective orexin receptor-2 (OX2R) agonist for the treatment of narcolepsy and other sleep disorders; and discovery-stage programs in certain other disease areas. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

The CEO & director of Dr. Saurabh Saha M.D., Ph.D.. is Centessa Pharmaceuticals plc (CNTA), and CFO & Sr. VP is Dr. Gregory M. Weinhoff M.B.A., M.D., MBA.

The promoters of Centessa Pharmaceuticals plc (CNTA) have pledged 0% of the total equity as on Mar-23.

Some of the close peers are:

No, TTM profit after tax of Centessa Pharmaceuticals plc (CNTA) was $-119 Mln.